Effect of rasagiline on the molecular composition of the excitatory postsynaptic density

European Journal of Pharmacology

Volumn 670, Issue 2-3, 2011, Pages 458-463

  Gardoni, Fabrizio ^a   Zianni, Elisa ^a   Eramo, Anna ^c   Canonico, Pier Luigi ^b   Di Luca, Monica ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c H LUNDBECK A S   (Denmark)

Author keywords

Neuroprotection; NMDA receptor; Parkinson's disease; Postsynaptic density; Rasagiline; Rat

Indexed keywords

ALPHA CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; AMPA RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; RASAGILINE; SAP102 PROTEIN; SAP97 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC DENSITY; HIPPOCAMPUS; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; HIPPOCAMPUS; INDANS; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; TIME FACTORS;

EID: 80755189958     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.09.028     Document Type: Article

References (28)

1. O. Bar-Am, M. Yogev-Falach, T. Amit, Y. Sagi, and M.B.H. Youdim Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo J. Neurochem. 89 2004 1119 1125 (Pubitemid 38715829)
2. O. Bar-Am, O. Weinreb, T. Amit, and M.B. Youdim Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine FASEB J. 19 2005 1899 1901 (Pubitemid 41598788)
3. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bédard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416 (Pubitemid 37543519)
4. J.J. Chen, and A.V. Ly Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease Am. J. Health Syst. Pharm. 63 2006 915 928 (Pubitemid 43764968)
5. J.J. Chen, D.M. Swope, and K. Dashtipour Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease Clin. Ther. 29 2007 1825 1849 (Pubitemid 350212811)
6. W. Dimpfel, and J.A. Hoffmann Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro BMC Pharmacol. 11 2011 2
7. A.W. Dunah, and D.G. Standaert Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane J. Neurosci. 21 2001 5546 5558 (Pubitemid 32692153)
8. F. Gardoni, L.H. Schrama, A. Kamal, W.H. Gispen, F. Cattabeni, and M. Di Luca Hippocampal synaptic plasticity involves competition between Ca2+/calmodulin-dependent protein kinase II and postsynaptic density 95 for binding to the NR2A subunit of the NMDA receptor J. Neurosci. 21 2001 1501 1509 (Pubitemid 32182190)
9. F. Gardoni, B. Picconi, V. Ghiglieri, F. Polli, V. Bagetta, G. Bernardi, F. Cattabeni, M. Di Luca, and P. Calabresi A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia J. Neurosci. 26 2006 2914 2922
10. F. Gardoni, E. Marcello, and M. Di Luca Postsynaptic density-membrane associated guanylate kinase proteins (PSD-MAGUKs) and their role in CNS disorders Neuroscience 158 2009 324 333
11. M.J. Kim, A.W. Dunah, Y.T. Wang, and M. Sheng Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking Neuron 246 2005 745 760 (Pubitemid 40733130)
12. C.G. Lau, and R.S. Zukin NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders Nat. Rev. Neurosci. 8 2007 413 426 (Pubitemid 46789232)
13. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
14. M. Naoi, and W. Maruyama Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease Expert Rev. Neurother. 9 2009 1233 1250
15. J.E. Nash, and J.M. Brotchie Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat Mov. Disord. 17 2002 455 466 (Pubitemid 36040956)
16. M. Niittykoski, A. Haapalinna, and J. Sirviö Selegiline reduces N-methyl-D-aspartic acid induced perturbation of neurotransmission but it leaves NMDA receptor dependent long-term potentiation intact in the hippocampus J. Neural Transm. 110 2003 1225 1240 (Pubitemid 37500745)
17. C.W. Olanow, R.A. Hauser, J. Jankovic, W. Langston, A. Lang, W. Poewe, E. Tolosa, F. Stocchi, E. Melamed, E. Eyal, and O. Rascol A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics Mov. Disord. 23 2008 2194 2201
18. C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, A. Lang, W. Langston, E. Melamed, W. Poewe, F. Stocchi, E. Tolosa ADAGIO Study Investigators A double-blind, delayed-start trial of rasagiline in Parkinson's disease N. Engl. J. Med. 361 2009 1268 1278
19. V. Paillé, B. Picconi, V. Bagetta, V. Ghiglieri, C. Sgobio, M. Di Filippo, M.T. Viscomi, C. Giampà, F.R. Fusco, F. Gardoni, G. Bernardi, P. Greengard, M. Di Luca, and P. Calabresi Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition J. Neurosci. 30 2010 14182 14193
20. B. Picconi, F. Gardoni, D. Centonze, D. Mauceri, M.A. Cenci, G. Bernardi, P. Calabresi, and M. Di Luca Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism J. Neurosci. 24 2004 5283 5291 (Pubitemid 38747668)
21. A.H. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol. 7 2008 97 109 (Pubitemid 350251942)
22. S.M. Schotanus, and K. Chergui NR2A-containing NMDA receptors depress glutamatergic synaptic transmission and evoked-dopamine release in the mouse striatum J. Neurochem. 106 2008 1758 1765
23. S.M. Schotanus, B.B. Fredholm, and K. Chergui NMDA depresses glutamatergic synaptic transmission in the striatum through the activation of adenosine A1 receptors: evidence from knockout mice Neuropharmacology 51 2006 272 282 (Pubitemid 44061891)
24. L. Verhagen Metman Recognition and treatment of response fluctuations in Parkinson's disease: review article Amino Acids 23 2002 141 145
25. O. Weinreb, T. Amit, O. Bar-Am, and M.B. Youdim Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy Ann. N. Y. Acad. Sci. 1122 2007 155 168 (Pubitemid 350249546)
26. O. Weinreb, T. Amit, Y. Sagi, N. Drigues, and M.B. Youdim Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain J. Neural Transm. 116 2009 1457 1472
27. O. Weinreb, S. Mandel, O. Bar-Am, M. Yogev-Falach, Y. Avramovich-Tirosh, T. Amit, and M.B. Youdim Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs Neurotherapeutics 6 2009 163 174
28. O. Weinreb, T. Amit, O. Bar-Am, and M.B. Youdim Rasagiline, a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity Prog. Neurobiol. 92 2010 330 344